Evidence map›Paper›PMID 32356139›Full record

ArticleCancer causes & control : CCC2020

Self-reported health and survival in older patients diagnosed with multiple myeloma.

Nadia A Nabulsi, Ali Alobaidi, Brian Talon, Alemseged A Asfaw, Jifang Zhou, Lisa K Sharp, Karen Sweiss, Pritesh R Patel, Naomi Y Ko, Brian C-H Chiu and 1 more

Open access · greenAbstract read
In one paragraph

Article in Cancer causes & control : CCC, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Nadia A NabulsiDepartment of Pharmacy Systems, Outcomes and Policy, Center for Pharmacoepidemiology and Pharmacoeconomic Research, University of Illinois at Chicago, 833 S. Wood St. MC 871, Chicago, IL, 60612, USA.
Ali AlobaidiDepartment of Pharmacy Systems, Outcomes and Policy, Center for Pharmacoepidemiology and Pharmacoeconomic Research, University of Illinois at Chicago, 833 S. Wood St. MC 871, Chicago, IL, 60612, USA.
Brian TalonDepartment of Pharmacy Systems, Outcomes and Policy, Center for Pharmacoepidemiology and Pharmacoeconomic Research, University of Illinois at Chicago, 833 S. Wood St. MC 871, Chicago, IL, 60612, USA.
Alemseged A AsfawDepartment of Pharmacy Systems, Outcomes and Policy, Center for Pharmacoepidemiology and Pharmacoeconomic Research, University of Illinois at Chicago, 833 S. Wood St. MC 871, Chicago, IL, 60612, USA.
Jifang ZhouDepartment of Pharmacy Systems, Outcomes and Policy, Center for Pharmacoepidemiology and Pharmacoeconomic Research, University of Illinois at Chicago, 833 S. Wood St. MC 871, Chicago, IL, 60612, USA.
Lisa K SharpDepartment of Pharmacy Systems, Outcomes and Policy, Center for Pharmacoepidemiology and Pharmacoeconomic Research, University of Illinois at Chicago, 833 S. Wood St. MC 871, Chicago, IL, 60612, USA.
Karen SweissDepartment of Pharmacy Practice, University of Illinois at Chicago, Chicago, IL, USA.
Pritesh R PatelDivision of Hematology and Oncology, Department of Medicine, University of Illinois at Chicago, Chicago, IL, USA.
Naomi Y KoSection of Hematology Oncology, Boston University School of Medicine, Boston, MA, USA.
Brian C-H ChiuDepartment of Public Health Sciences, The University of Chicago, Chicago, IL, USA.
Gregory S CalipDepartment of Pharmacy Systems, Outcomes and Policy, Center for Pharmacoepidemiology and Pharmacoeconomic Research, University of Illinois at Chicago, 833 S. Wood St. MC 871, Chicago, IL, 60612, USA. gcalip@uic.edu.ORCID https://orcid.org/0000-0002-7744-3518
University of Illinois Chicago · USBoston University · USChicago Department of Public Health · US

Funding

Institutional Career DevelopmentKL2TR002002 · NCATS · UNIVERSITY OF ILLINOIS AT CHICAGO · PI PHILLIPS, SHANE A · 2016 to 2024
$6.8M
Epigenomic markers of circulating cell-free DNA and treatment outcome in multiple myelomaR01CA223662 · NCI · UNIVERSITY OF CHICAGO · PI CHIU, BRIAN C-H, ZHANG, WEI · 2018 to 2022
$3.2M
Risk of venous thromboembolism following diagnosis and treatment of multiple myeloma: differences by raceR21HL140531 · NHLBI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI CALIP, GREGORY SAMPANG · 2018 to 2019
$439k
NCATS NIH HHS KL2 TR002002NCATS NIH HHS KL2TR002002NCI NIH HHS R01 CA223662NCI NIH HHS R01CA223662NHLBI NIH HHS R21 HL140531NHLBI NIH HHS R21HL140531
6 · The paper itself

Abstract

purposePatient-reported outcomes such as self-reported health (SRH) are important in understanding quality cancer care, yet little is known about links between SRH and outcomes in older patients with multiple myeloma (MM). We evaluated associations between SRH and mortality among older patients with MM.

methodsWe analyzed a retrospective cohort of patients ages ≥ 65 years diagnosed with first primary MM using the Surveillance, Epidemiology, and End Results (SEER)-Medicare Health Outcomes Survey (MHOS) data resource. Pre-diagnosis SRH was grouped as high (excellent/very good/good) or low (fair/poor). We used Cox proportional hazards models to estimate adjusted hazard ratios (HR) and 95% confidence intervals (CI) for associations between SRH and all-cause and MM-specific mortality.

resultsOf 521 MM patients with mean (SD) age at diagnosis of 76.8 (6.1) years, 32% reported low SRH. In multivariable analyses, low SRH was suggestive of modest increased risks of all-cause mortality (HR 1.32, 95% CI 1.02-1.71) and MM-specific mortality (HR 1.22, 95% CI 0.87-1.70) compared to high SRH.

conclusionFindings suggest that low pre-diagnosis SRH is highly prevalent among older patients with MM and is associated with modestly increased all-cause mortality. Additional research is needed to address quality of life and modifiable factors that may accompany poor SRH in older patients with MM.

Indexed as

Health StatusAgedAged, 80 and overCohort StudiesFemaleHumansMaleMedicareMultiple MyelomaProportional Hazards ModelsQuality of LifeRetrospective StudiesSEER ProgramSelf ReportSurveys and QuestionnairesUnited StatesCancer-specific mortalityMultiple myelomaSelf-reported healthSurvival

Identifiers

PMID32356139
PMCPMC7274896
OpenAlexW3023328882

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.